Sulforaphane Bioavailability and Chemopreventive Activity in Men Presenting for Biopsy of the Prostate Gland

A Randomized Controlled Trial

Zhenzhen Zhang, Mark Garzotto, Edward W. Davis, Motomi (Tomi) Mori, Wesley A. Stoller, Paige E. Farris, Carmen P. Wong, Laura M. Beaver, George Thomas, David E. Williams, Roderick H. Dashwood, David A. Hendrix, Emily Ho, Jackilen (Jackie) Shannon

Research output: Contribution to journalArticle

Abstract

Previous studies suggest compounds such as sulforaphane (SFN) derived from cruciferous vegetables may prevent prostate cancer development and progression. This study evaluated the effect of broccoli sprout extract (BSE) supplementation on blood histone deacetylase (HDAC) activity, prostate RNA gene expression, and tissue biomarkers (histone H3 lysine 18 acetylation (H3K18ac), HDAC3, HDAC6, Ki67, and p21). A total of 98 men scheduled for prostate biopsy were allocated into either BSE (200 µmol daily) or a placebo in our double-blind, randomized controlled trial. We used nonparametric tests to evaluate the differences of blood HDAC activity and prostate tissue immunohistochemistry biomarkers between treatment groups. Further, we performed RNA-Seq analysis on the prostate biopsies and identified 40 differentially expressed genes correlated with BSE treatment, including downregulation of two genes previously implicated in prostate cancer development, AMACR and ARLNC1. Although urine and plasma SFN isothiocyanates and individual SFN metabolites were statistically higher in the treatment group, our results did not show a significant difference in HDAC activity or prostate tissue biomarkers. This study indicates BSE supplementation correlates with changes in gene expression but not with several other prostate cancer biomarkers. More research is required to fully understand the chemopreventive effects of BSE supplementation on prostate cancer.

Original languageEnglish (US)
JournalNutrition and Cancer
DOIs
StatePublished - Jan 1 2019

Fingerprint

Brassica
Biological Availability
Prostate
Randomized Controlled Trials
Histone Deacetylases
Prostatic Neoplasms
Biopsy
Biomarkers
RNA
Isothiocyanates
Gene Expression
Acetylation
Tumor Biomarkers
Vegetables
Histones
Genes
Lysine
Therapeutics
Down-Regulation
Immunohistochemistry

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Oncology
  • Nutrition and Dietetics
  • Cancer Research

Cite this

Sulforaphane Bioavailability and Chemopreventive Activity in Men Presenting for Biopsy of the Prostate Gland : A Randomized Controlled Trial. / Zhang, Zhenzhen; Garzotto, Mark; Davis, Edward W.; Mori, Motomi (Tomi); Stoller, Wesley A.; Farris, Paige E.; Wong, Carmen P.; Beaver, Laura M.; Thomas, George; Williams, David E.; Dashwood, Roderick H.; Hendrix, David A.; Ho, Emily; Shannon, Jackilen (Jackie).

In: Nutrition and Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Zhang, Zhenzhen ; Garzotto, Mark ; Davis, Edward W. ; Mori, Motomi (Tomi) ; Stoller, Wesley A. ; Farris, Paige E. ; Wong, Carmen P. ; Beaver, Laura M. ; Thomas, George ; Williams, David E. ; Dashwood, Roderick H. ; Hendrix, David A. ; Ho, Emily ; Shannon, Jackilen (Jackie). / Sulforaphane Bioavailability and Chemopreventive Activity in Men Presenting for Biopsy of the Prostate Gland : A Randomized Controlled Trial. In: Nutrition and Cancer. 2019.
@article{1e70d649f36a4e3485b562697dd6ec9a,
title = "Sulforaphane Bioavailability and Chemopreventive Activity in Men Presenting for Biopsy of the Prostate Gland: A Randomized Controlled Trial",
abstract = "Previous studies suggest compounds such as sulforaphane (SFN) derived from cruciferous vegetables may prevent prostate cancer development and progression. This study evaluated the effect of broccoli sprout extract (BSE) supplementation on blood histone deacetylase (HDAC) activity, prostate RNA gene expression, and tissue biomarkers (histone H3 lysine 18 acetylation (H3K18ac), HDAC3, HDAC6, Ki67, and p21). A total of 98 men scheduled for prostate biopsy were allocated into either BSE (200 µmol daily) or a placebo in our double-blind, randomized controlled trial. We used nonparametric tests to evaluate the differences of blood HDAC activity and prostate tissue immunohistochemistry biomarkers between treatment groups. Further, we performed RNA-Seq analysis on the prostate biopsies and identified 40 differentially expressed genes correlated with BSE treatment, including downregulation of two genes previously implicated in prostate cancer development, AMACR and ARLNC1. Although urine and plasma SFN isothiocyanates and individual SFN metabolites were statistically higher in the treatment group, our results did not show a significant difference in HDAC activity or prostate tissue biomarkers. This study indicates BSE supplementation correlates with changes in gene expression but not with several other prostate cancer biomarkers. More research is required to fully understand the chemopreventive effects of BSE supplementation on prostate cancer.",
author = "Zhenzhen Zhang and Mark Garzotto and Davis, {Edward W.} and Mori, {Motomi (Tomi)} and Stoller, {Wesley A.} and Farris, {Paige E.} and Wong, {Carmen P.} and Beaver, {Laura M.} and George Thomas and Williams, {David E.} and Dashwood, {Roderick H.} and Hendrix, {David A.} and Emily Ho and Shannon, {Jackilen (Jackie)}",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/01635581.2019.1619783",
language = "English (US)",
journal = "Nutrition and Cancer",
issn = "0163-5581",
publisher = "Routledge",

}

TY - JOUR

T1 - Sulforaphane Bioavailability and Chemopreventive Activity in Men Presenting for Biopsy of the Prostate Gland

T2 - A Randomized Controlled Trial

AU - Zhang, Zhenzhen

AU - Garzotto, Mark

AU - Davis, Edward W.

AU - Mori, Motomi (Tomi)

AU - Stoller, Wesley A.

AU - Farris, Paige E.

AU - Wong, Carmen P.

AU - Beaver, Laura M.

AU - Thomas, George

AU - Williams, David E.

AU - Dashwood, Roderick H.

AU - Hendrix, David A.

AU - Ho, Emily

AU - Shannon, Jackilen (Jackie)

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Previous studies suggest compounds such as sulforaphane (SFN) derived from cruciferous vegetables may prevent prostate cancer development and progression. This study evaluated the effect of broccoli sprout extract (BSE) supplementation on blood histone deacetylase (HDAC) activity, prostate RNA gene expression, and tissue biomarkers (histone H3 lysine 18 acetylation (H3K18ac), HDAC3, HDAC6, Ki67, and p21). A total of 98 men scheduled for prostate biopsy were allocated into either BSE (200 µmol daily) or a placebo in our double-blind, randomized controlled trial. We used nonparametric tests to evaluate the differences of blood HDAC activity and prostate tissue immunohistochemistry biomarkers between treatment groups. Further, we performed RNA-Seq analysis on the prostate biopsies and identified 40 differentially expressed genes correlated with BSE treatment, including downregulation of two genes previously implicated in prostate cancer development, AMACR and ARLNC1. Although urine and plasma SFN isothiocyanates and individual SFN metabolites were statistically higher in the treatment group, our results did not show a significant difference in HDAC activity or prostate tissue biomarkers. This study indicates BSE supplementation correlates with changes in gene expression but not with several other prostate cancer biomarkers. More research is required to fully understand the chemopreventive effects of BSE supplementation on prostate cancer.

AB - Previous studies suggest compounds such as sulforaphane (SFN) derived from cruciferous vegetables may prevent prostate cancer development and progression. This study evaluated the effect of broccoli sprout extract (BSE) supplementation on blood histone deacetylase (HDAC) activity, prostate RNA gene expression, and tissue biomarkers (histone H3 lysine 18 acetylation (H3K18ac), HDAC3, HDAC6, Ki67, and p21). A total of 98 men scheduled for prostate biopsy were allocated into either BSE (200 µmol daily) or a placebo in our double-blind, randomized controlled trial. We used nonparametric tests to evaluate the differences of blood HDAC activity and prostate tissue immunohistochemistry biomarkers between treatment groups. Further, we performed RNA-Seq analysis on the prostate biopsies and identified 40 differentially expressed genes correlated with BSE treatment, including downregulation of two genes previously implicated in prostate cancer development, AMACR and ARLNC1. Although urine and plasma SFN isothiocyanates and individual SFN metabolites were statistically higher in the treatment group, our results did not show a significant difference in HDAC activity or prostate tissue biomarkers. This study indicates BSE supplementation correlates with changes in gene expression but not with several other prostate cancer biomarkers. More research is required to fully understand the chemopreventive effects of BSE supplementation on prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85066615439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066615439&partnerID=8YFLogxK

U2 - 10.1080/01635581.2019.1619783

DO - 10.1080/01635581.2019.1619783

M3 - Article

JO - Nutrition and Cancer

JF - Nutrition and Cancer

SN - 0163-5581

ER -